For investors looking for growth, biotech stocks are a great place to start one’s search. This is a sector that’s seen its valuation multiples decline in many cases to a greater extent than the overall market. Thus, while many biotech stocks exhibit strong growth trajectories, these companies often trade at bargain prices. Much of that has…

Source: JHVEPhoto / Shutterstock.com Teva Pharmaceuticals (NYSE:TEVA) stock is sliding on Monday after the company announced Richard Francis as its newest president and CEO. Francis will take over as the president and CEO of Teva Pharmaceuticals starting on Jan. 1, 2023. This will have him replacing Kåre Schultz, who will retire from those roles on…

Because Covid-19 has dominated the news cycle for almost two years, many investors have ignored drug stocks outside of that domain. Betting on vaccine suppliers like Moderna (NASDAQ:MRNA) or BioNTech (NASDAQ:BNTX) has paid off — those stocks more than tripled at their peak. Since August, buying interest in these stocks has waned. The drop in…

Crispr Therapeutics (NASDAQ:CRSP) stock is falling on Wednesday following the release of new results from a Phase 1 clinical trial. Source: Shutterstock These results were mostly positive with the company reporting 58% overall response rate and 38% complete response rate in large B-cell lymphoma. The drug was also well-tolerated with only two patients suffering Grade…

Biotech stocks are infamously one of the most volatile sectors in the stock market. Investors often venture into speculative companies with no proven pipelines. Emerging firms with a pipeline of drugs and products still in the clinical phase post little to no revenue. They raise cash by tapping capital markets to pay for research and…

Investors looking to build their wealth over the long term have countless options in the market today, including domestic and international stocks. There are physical assets, such as real estate, in addition to the thousands of exchange-traded products available, and of course, thousands of individual stocks investors can buy. Not all are created equal, of…

For the past three months, the only question with cannabis firm Tilray (NASDAQ:TLRY) was whether it was better to buy the stock or smoke its products. Source: Shutterstock But that all changed (supposedly) yesterday when it announced its fiscal Q4 earnings. The day after the announcement, the stock rallied more than 25% after getting pounded…

In general, Dividend Aristocrats are the foundation for the portfolios of most serious dividend growth investors. European Dividend aristocrats are typically blue-chip stocks that have proven to reward shareholders with rising dividends over a long period. While historic dividend payment does not guarantee future distributions, it can help investors when accessing the likelihood of a…

Biotechnology has always been one of the most relevant sectors. But with the onslaught of the novel coronavirus pandemic, more people have tuned into this vital segment of the economy. Hopefully, as Covid-19 fades permanently away, we may end up turning to companies like CRISPR Therapeutics (NASDAQ:CRSP) for resolving chronic issues instead of addressing acute…

Psychedelic therapy developer Mind Medicine (NASDAQ:MNMD) stock has been on fire this year, generating more than 100% in returns in the past six months. Source: local_doctor / Shutterstock.com It currently has the most diversified pipeline of psychedelics in clinical development and R&D, tackling mental health. There has been a steep rise in mental health ailments…